JP Morgan Maintains Overweight on Xenon Pharmaceuticals, Raises Price Target to $82
Benzinga Newsdesk 5 months ago
NewsPrice TargetAnalyst Ratings
JP Morgan analyst Tessa Romero maintains Xenon Pharmaceuticals (NASDAQ:XENE) with a Overweight and raises the price target from $80 to $82.
JP Morgan analyst Tessa Romero maintains Xenon Pharmaceuticals (NASDAQ:XENE) with a Overweight and raises the price target from $80 to $82.